These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9730052)

  • 1. Exposure to stress alters the effects of dynorphins in the hot plate test.
    Starec M; Nejedlý A; Málek J; Rosina J; Gojisová E; Krsiak M
    Physiol Res; 1997; 46(6):451-7. PubMed ID: 9730052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia.
    Starec M; Rosina J; Málek J; Krsiak M
    Physiol Res; 1996; 45(6):433-8. PubMed ID: 9085373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic effects of dynorphin-A and morphine in mice.
    Nakazawa T; Ikeda M; Kaneko T; Yamatsu K
    Peptides; 1985; 6(1):75-8. PubMed ID: 2859574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [D-Pro10]-dynorphin(1-11) is a kappa-selective opioid analgesic in mice.
    Gairin JE; Gout R; Meunier JC; Cros J
    J Pharmacol Exp Ther; 1988 Jun; 245(3):995-1001. PubMed ID: 2898527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Des-Tyr1]dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay.
    Hooke LP; He L; Lee NM
    J Pharmacol Exp Ther; 1995 May; 273(2):802-7. PubMed ID: 7752083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-Ala2,F5Phe4-dynorphin amide, an opiate with analgesic and toxic properties.
    Kostrzewa RM; Brus R; Coy DH; Criswell H; Coogan PS; Kastin AJ
    Pol J Pharmacol Pharm; 1992; 44(2):109-20. PubMed ID: 1357636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Opioid Peptides on Changes in Lipid Metabolism in Rats Subjected to Swimming Stress.
    Solin AV; Lyashev AY; Lyashev YD
    Bull Exp Biol Med; 2017 Jan; 162(3):313-315. PubMed ID: 28091903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidimensional behavioral analyses show dynorphin A-(1-13) modulation of methamphetamine-induced behaviors in mice.
    Ukai M; Toyoshi T; Kameyama T
    Eur J Pharmacol; 1992 Nov; 222(1):7-12. PubMed ID: 1361442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat.
    Tiseo PJ; Geller EB; Adler MW
    J Pharmacol Exp Ther; 1988 Aug; 246(2):449-53. PubMed ID: 2900324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulators of pain in the spinal cord.
    Jen MF; Lu CH; Huang L; Han JS
    NIDA Res Monogr; 1986; 75():457-60. PubMed ID: 2893278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynorphin-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat.
    Haaf JA; Maigret C; Andringa-Bakker EA; van Wimersma Greidanus TB
    Acta Endocrinol (Copenh); 1987 Jan; 114(1):96-101. PubMed ID: 2880444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral changes induced by stressful situations: effects of enkephalins, dynorphin, and their interactions.
    Katoh A; Nabeshima T; Kameyama T
    J Pharmacol Exp Ther; 1990 May; 253(2):600-7. PubMed ID: 1971017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of dynorphin A (1-13) on lipid peroxidation and antioxidant enzymes activity in the immobilization stress of different duration].
    Solin AV; Liashev IuD
    Ross Fiziol Zh Im I M Sechenova; 2014 Jan; 100(1):54-60. PubMed ID: 25464721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynorphin A and related peptides administered intrathecally in the rat: a search for putative kappa opiate receptor activity.
    Stevens CW; Yaksh TL
    J Pharmacol Exp Ther; 1986 Sep; 238(3):833-8. PubMed ID: 2875172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of functionalized niosomes for brain targeting of dynorphin-B.
    Bragagni M; Mennini N; Furlanetto S; Orlandini S; Ghelardini C; Mura P
    Eur J Pharm Biopharm; 2014 May; 87(1):73-9. PubMed ID: 24462793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal dynorphin A (1-13) and (3-13) reduce spinal cord blood flow by non-opioid mechanisms.
    Long JB; Kinney RC; Malcolm DS; Graeber GM; Holaday JW
    NIDA Res Monogr; 1986; 75():524-6. PubMed ID: 2893280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys.
    Butelman ER; Harris TJ; Perez A; Kreek MJ
    J Pharmacol Exp Ther; 1999 Aug; 290(2):678-86. PubMed ID: 10411578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration.
    Hemstapat K; Le L; Edwards SR; Smith MT
    Pharmacol Biochem Behav; 2009 Oct; 93(4):498-505. PubMed ID: 19580825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynorphin A (1-13): in vivo opioid antagonist actions and non-opioid anticonvulsant effects in the rat flurothyl test.
    Tortella FC; Holaday JW
    NIDA Res Monogr; 1986; 75():539-42. PubMed ID: 2893282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.